Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Inegy

Inegy is a new product that containes Simvastatin and Ezetimibe and it is licensed for hypercholesterolaemia.

The combination product would mean that a patient already taking the two separate products, or a patient who is not reaching target on a statin alone could be prescribed a single tablet that would have two cholesterol lowering effects.

However, the combination product cost approximately £8 per month more than the separate ingredients. This is equivalent to an additional 2 patients on treatment with the statin alone.

Action: At this time there can be no good reason to use this product over the separate ingredients, except perhaps for those patients with a known and significant compliance problem.

Share 'Inegy' on Email Share 'Inegy' on Delicious Share 'Inegy' on Digg Share 'Inegy' on Facebook Share 'Inegy' on Google+ Share 'Inegy' on reddit Share 'Inegy' on StumbleUpon Share 'Inegy' on Twitter

atomic-wealth

No Comments to “Inegy”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.

atomic-wealth
fond-illness
summer